Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome.
EFSA‐ECHA Guidance
Endocrine disruption
adverse outcome pathway (AOP)
uterine adenocarcinoma
Journal
EFSA journal. European Food Safety Authority
ISSN: 1831-4732
Titre abrégé: EFSA J
Pays: United States
ID NLM: 101642076
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
epublish
Résumé
Development of adverse outcome pathways (AOPs) for uterine adenocarcinoma can provide a practical tool to implement the EFSA-ECHA Guidance (2018) for the identification of endocrine disruptors in the context of Regulations (EU) No 528/2012 and (EC) No 1107/2009. AOPs can give indications about the strength of the relationship between an adverse outcome (intended as a human health outcome) and chemicals (pesticides but not only) affecting the pathways. In this scientific opinion, the PPR Panel explored the development of AOPs for uterine adenocarcinoma. An evidence-based approach methodology was applied, and literature reviews were produced using a structured framework assuring transparency, objectivity, and comprehensiveness. Several AOPs were developed; these converged to a common critical node, that is increased estradiol availability in the uterus followed by estrogen receptor activation in the endometrium; therefore, a putative AOP network was considered. An uncertainty analysis and a probabilistic quantification of the weight of evidence have been carried out via expert knowledge elicitation for each set of MIEs/KEs/KERs included in individual AOPs. The collected data on the AOP network were evaluated qualitatively, whereas a quantitative uncertainty analysis for weight of the AOP network certainty has not been performed. Recommendations are provided, including exploring further the uncertainties identified in the AOPs and putative AOP network; further methodological developments for quantifying the certainty of the KERs and of the overall AOPs and AOP network; and investigating of NAMs applications in the context of some of the MIEs/KEs currently part of the putative AOP network developed.
Identifiants
pubmed: 36818642
doi: 10.2903/j.efsa.2023.7744
pii: EFS27744
pmc: PMC9926893
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e07744Informations de copyright
© 2023 European Food Safety Authority. EFSA Journal published by Wiley‐VCH GmbH on behalf of European Food Safety Authority.
Références
Int J Mol Sci. 2018 Apr 10;19(4):
pubmed: 29642629
Toxicol Pathol. 2017 Jan;45(1):206-215
pubmed: 27753638
Oncol Rep. 2006 Dec;16(6):1343-8
pubmed: 17089059
Ann Intern Med. 1995 May 15;122(10):778-88
pubmed: 7717601
J Pathol. 2007 Jan;211(2):219-31
pubmed: 17200943
J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):225-30
pubmed: 14623515
Mod Pathol. 1997 Oct;10(10):963-8
pubmed: 9346174
Am J Clin Nutr. 1987 Jan;45(1 Suppl):290-5
pubmed: 3799519
Mod Pathol. 2000 Apr;13(4):379-88
pubmed: 10786803
Int J Cancer. 1992 Dec 2;52(6):941-9
pubmed: 1459735
Vet Pathol. 2008 Mar;45(2):217-25
pubmed: 18424838
Adv Exp Med Biol. 2017;943:243-259
pubmed: 27910070
Endocr Rev. 1990 May;11(2):266-301
pubmed: 2114281
Vet Pathol. 1981 Nov;18(6):707-13
pubmed: 7292893
Carcinogenesis. 2002 Sep;23(9):1549-55
pubmed: 12189200
Cancer Lett. 2000 Oct 1;158(2):133-9
pubmed: 10960762
Endocrine. 1999 Dec;11(3):217-33
pubmed: 10786818
Endocrinology. 2006 Jun;147(6 Suppl):S11-7
pubmed: 16690809
Exp Toxicol Pathol. 2016 Feb-Mar;68(2-3):143-7
pubmed: 26655996
Breast Cancer Res Treat. 1994;30(1):19-29
pubmed: 7949202
J Cancer Res Clin Oncol. 1993;119(8):450-6
pubmed: 8509435
J Endocrinol. 2015 May;225(2):69-76
pubmed: 25767055
Cancer Lett. 2004 Jul 28;211(1):1-9
pubmed: 15194211
J Natl Cancer Inst. 1985 Jan;74(1):121-35
pubmed: 3855473
Toxicol Pathol. 1995 May-Jun;23(3):287-302
pubmed: 7659953
Mol Cancer Res. 2016 Sep;14(9):849-58
pubmed: 27259717
ALTEX. 2022 Mar 01;39(3):499–518
pubmed: 35258090
J Toxicol Pathol. 2015 Oct;28(4):207-16
pubmed: 26538810
J Mol Endocrinol. 2018 Aug;61(2):T271-T283
pubmed: 29764919
Cancer Med. 2015 Jul;4(7):1039-50
pubmed: 25809780
Eur J Cancer Clin Oncol. 1989 Dec;25(12):1953-9
pubmed: 2632276
Mol Endocrinol. 2013 Oct;27(10):1666-77
pubmed: 24002655
J Reprod Dev. 2009 Apr;55(2):105-9
pubmed: 19106489
Food Chem Toxicol. 1995;33 Suppl 1:1S-100S
pubmed: 7713457
Environ Toxicol Chem. 2018 Jun;37(6):1723-1733
pubmed: 29488651
J Toxicol Pathol. 2014;27(3-4 Suppl):1S-107S
pubmed: 25516636
Endocr Relat Cancer. 2003 Mar;10(1):23-42
pubmed: 12653669
Dis Model Mech. 2013 May;6(3):710-20
pubmed: 23471917
Anim Reprod Sci. 2011 Apr;124(3-4):229-36
pubmed: 20869180
Sci Rep. 2015 Oct 15;5:14958
pubmed: 26468779
Tohoku J Exp Med. 1999 Oct;189(2):87-93
pubmed: 10775052
Reprod Toxicol. 2017 Mar;68:85-104
pubmed: 27421580
Horm Cancer. 2019 Jun;10(2-3):51-63
pubmed: 30712080
Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(2):83-9
pubmed: 1710855
Semin Reprod Med. 2010 Jan;28(1):81-90
pubmed: 20104432
Endocrinology. 2019 Jun 1;160(6):1480-1491
pubmed: 31083714
Drug Chem Toxicol. 2000 Nov;23(4):575-601
pubmed: 11071396
Mod Pathol. 2000 Mar;13(3):295-308
pubmed: 10757340
Endocrinology. 2018 Sep 1;159(9):3209-3218
pubmed: 30010832
Neuropharmacology. 2010 Jan;58(1):314-20
pubmed: 19559035
Nat Rev Dis Primers. 2015 Apr 23;1:15004
pubmed: 27188659
Cancer Causes Control. 2001 Nov;12(9):837-45
pubmed: 11714112
Dev Biol. 2001 Oct 15;238(2):224-38
pubmed: 11784006
Cancer. 2006 Feb 15;106(4):812-9
pubmed: 16400639
Cancer Lett. 1995 Jun 8;92(2):223-7
pubmed: 7600534
Development. 2004 Apr;131(7):1639-49
pubmed: 14998922
Gynecol Endocrinol. 2016;32(5):403-7
pubmed: 26680656
Br Med J. 1977 Dec 17;2(6102):1605
pubmed: 589369
J Clin Endocrinol Metab. 1984 Feb;58(2):378-83
pubmed: 6420438
Toxicol Pathol. 1995 May-Jun;23(3):269-86
pubmed: 7659952
Differentiation. 2011 Oct;82(3):117-26
pubmed: 21612855
Jpn J Cancer Res. 1993 Sep;84(9):951-5
pubmed: 8407561
J Mol Endocrinol. 2016 Jul;57(1):R19-33
pubmed: 27067638
Obstet Gynecol. 2012 Aug;120(2 Pt 1):383-97
pubmed: 22825101
Environ Sci Technol. 2020 Jul 21;54(14):8491-8499
pubmed: 32584560
Mol Cell Endocrinol. 2019 Jun 1;489:66-81
pubmed: 30336189
Chem Res Toxicol. 1999 Dec;12(12):1247-53
pubmed: 10604875
Endocr Rev. 2008 Feb;29(1):1-41
pubmed: 18057139
Endocr Relat Cancer. 2009 Mar;16(1):99-111
pubmed: 19075038
Endocrine. 2000 Dec;13(3):315-23
pubmed: 11216643
Cancer Causes Control. 2010 Jul;21(7):999-1007
pubmed: 20204493
Toxicol Pathol. 2015 Aug;43(6):865-71
pubmed: 26157037
Cancer Res. 2014 Jan 1;74(1):15-23
pubmed: 24322983
Oncology. 1995 Jul-Aug;52(4):319-25
pubmed: 7777247
Steroids. 1987 Jul-Sep;50(1-3):297-306
pubmed: 3504065
Mol Endocrinol. 2001 Dec;15(12):2093-105
pubmed: 11731611
Toxicology. 2006 Nov 10;228(1):98-108
pubmed: 16996190
Regul Toxicol Pharmacol. 2016 Jun;77:143-59
pubmed: 26828025
Histol Histopathol. 2013 Oct;28(10):1245-56
pubmed: 23719713
Adv Cancer Res. 2008;101:93-126
pubmed: 19055944
J Natl Cancer Inst. 1987 Jun;78(6):1245-51
pubmed: 3473261
Endocr Rev. 2015 Oct;36(5):526-63
pubmed: 26213785
Carcinogenesis. 2004 Nov;25(11):2257-64
pubmed: 15240508
Cancer Res. 1970 Sep;30(9):2310-3
pubmed: 5529115
N Engl J Med. 2011 Oct 6;365(14):1304-14
pubmed: 21991952
Jpn J Cancer Res. 1991 Dec;82(12):1391-6
pubmed: 1778763
J Steroid Biochem Mol Biol. 2011 May;125(1-2):66-82
pubmed: 21193039
J Pathol. 2017 Jun;242(2):152-164
pubmed: 28349562
Sci China Life Sci. 2012 Aug;55(8):653-8
pubmed: 22932880
Crit Rev Clin Lab Sci. 2017 Mar;54(2):73-86
pubmed: 27960570
Mutat Res. 1974 Sep;24(3):219-26
pubmed: 4415481
Biol Reprod. 1984 Sep;31(2):399-413
pubmed: 6541064
Am J Pathol. 1995 Feb;146(2):491-500
pubmed: 7856758
Endocr Rev. 2019 Apr 1;40(2):369-416
pubmed: 30496379
Mol Cancer Ther. 2013 Dec;12(12):2917-28
pubmed: 24222661
Toxicol Pathol. 1994 May-Jun;22(3):261-9
pubmed: 7817117
Vet Q. 1984 Sep;6(4):200-8
pubmed: 6388139
Toxicol Pathol. 2012 Aug;40(6):926-30
pubmed: 22585942
Dis Markers. 2022 Nov 28;2022:2334338
pubmed: 36479043
Birth Defects Res C Embryo Today. 2013 Jun;99(2):134-46
pubmed: 23897597
Endocrinology. 2022 Mar 1;163(3):
pubmed: 35134138
Semin Oncol Nurs. 2019 Apr;35(2):157-165
pubmed: 30867105
Int J Gynecol Cancer. 2011 Nov;21(8):1343-9
pubmed: 21989218
Ann N Y Acad Sci. 2001 Dec;948:9-12
pubmed: 11795399
Toxicol Sci. 2021 Nov 24;184(2):183-190
pubmed: 34534351
Gynecol Oncol. 2014 Aug;134(2):385-92
pubmed: 24905773
J Toxicol Sci. 1994 Aug;19(3):119-32
pubmed: 7966449
Exp Toxicol Pathol. 1998 Jun;50(3):185-90
pubmed: 9681648
Pharmacol Rev. 2005 Sep;57(3):359-83
pubmed: 16109840
J Clin Endocrinol Metab. 2001 Jul;86(7):3436-43
pubmed: 11443221
Toxicol Pathol. 2012 Aug;40(6):943-50
pubmed: 22569585
Am J Pathol. 2002 Apr;160(4):1481-6
pubmed: 11943731
Clin Cancer Res. 2017 Dec 1;23(23):7232-7241
pubmed: 28939739
Lab Anim Sci. 1983 Jun;33(3):273-86
pubmed: 6876733
Physiology (Bethesda). 2016 Jul;31(4):258-69
pubmed: 27252161
Eur J Obstet Gynecol Reprod Biol. 2002 Nov 15;105(2):161-5
pubmed: 12381480
Annu Rev Pharmacol Toxicol. 1996;36:203-32
pubmed: 8725388
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Toxicol Pathol. 1994 May-Jun;22(3):300-15
pubmed: 7817120
EFSA J. 2018 Jun 07;16(6):e05311
pubmed: 32625944
J Cancer. 2015 Sep 01;6(10):1058-65
pubmed: 26366220
Mol Hum Reprod. 2013 Sep;19(9):547-58
pubmed: 23619340
Curr Drug Metab. 2006 Jan;7(1):83-104
pubmed: 16454694
Oncogene. 2013 Apr 25;32(17):2211-9
pubmed: 22689059
Cancer Res. 2001 Jun 1;61(11):4325-8
pubmed: 11389053
Regul Toxicol Pharmacol. 2016 Feb;74 Suppl:S44-56
pubmed: 26148665
Cancer Res. 1982 May;42(5):2003-11
pubmed: 7066910
Biol Reprod. 1999 Jul;61(1):91-100
pubmed: 10377036
N Engl J Med. 2009 Jan 15;360(3):268-79
pubmed: 19144942
Cancer Cell. 2004 Jun;5(6):533-8
pubmed: 15193256
Cancer Res. 1990 Dec 1;50(23):7677-81
pubmed: 2174729
J Clin Oncol. 2016 Dec 10;34(35):4225-4230
pubmed: 27903150
Gynecol Endocrinol. 2019 May;35(5):370-375
pubmed: 30668178
J Steroid Biochem Mol Biol. 2014 Jul;142:132-41
pubmed: 23583565
Cancer Manag Res. 2020 Aug 04;12:6767-6777
pubmed: 32801905
Int J Cancer. 2015 Mar 15;136(6):1245-53
pubmed: 24488862
Mol Cell Endocrinol. 2009 Feb 5;299(1):32-8
pubmed: 19063938
Methods. 2015 May;77-78:31-40
pubmed: 25461816
Neuroendocrinology. 1989 Sep;50(3):308-14
pubmed: 2797384
Dis Model Mech. 2010 Mar-Apr;3(3-4):181-93
pubmed: 20142330
Environ Health Perspect. 2011 Nov;119(11):1575-82
pubmed: 21810550
Int J Mol Sci. 2018 Aug 09;19(8):
pubmed: 30096949
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
J Natl Cancer Inst. 1980 May;64(5):1209-14
pubmed: 6929019
Cancer Res. 2014 Dec 15;74(24):7371-82
pubmed: 25377472
Cancer Res. 2008 Jul 15;68(14):5619-27
pubmed: 18632614
Int J Gynecol Cancer. 2005 May-Jun;15(3):537-41
pubmed: 15882182
Toxicol Pathol. 2018 Jul;46(5):574-596
pubmed: 29895210
Toxicol Rep. 2014 Nov 20;1:1202-1212
pubmed: 28962330
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Am J Pathol. 2012 Jun;180(6):2536-47
pubmed: 22503752
Contraception. 1983 Apr;27(4):409-21
pubmed: 6851569
Cancer Res. 2000 Jan 15;60(2):235-7
pubmed: 10667565
J Natl Cancer Inst. 1996 Aug 21;88(16):1127-35
pubmed: 8757192